Johnson & Johnson Reports 75% Tumor Response Rate for JNJ-6143
Johnson & Johnson reported a 75% tumor response rate for its investigational JNJ-6143 in advanced prostate cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.